{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:29:06Z","timestamp":1777930146000,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Bei einem lO\u00bej\u00e4hrigem M\u00e4dchen mit einer T-ALL und extremer Leukozytose (400000 Zellen\/\u03bcl) beobachteten wir im Rahmen eines Tumorlysesyndromes eine Hyperphosphatamie und Hypokalz\u00e4mie mit tetanischen Kr\u00e4mpfen. Die klinisch notwendige Applikation von Kalziumgluconat f\u00fchrte zu einer deutlichen \u00dcberschreitung des Kalzium-Phosphat-L\u00f6slichkeitsproduktes und hatte intravasale Verkalkungen zur Folge. Die Ursache der Hyperphosphatamie ist in dem schnellen Zerfall der T-Lymphoblasten mit hohem Phosphatanteil zu sehen. Bei unserer Patientin kam es im weiteren Verlauf zu einem Multiorganversagen, an dem sie verstarb. Regelm\u00e4\u00dfige Urinphosphatbestimmungen k\u00f6nnen den tats\u00e4chlichen Phosphatanteil im Organismus wiedergeben und so m\u00f6glicherweise zu fr\u00fchzeitigen therapeutischen Interventionen f\u00fchren.<\/jats:p>","DOI":"10.1159\/000216604","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T10:05:34Z","timestamp":1240999534000},"page":"64-68","source":"Crossref","is-referenced-by-count":2,"title":["Extreme Hyperphosphat\u00e4mie mit Hypokalz\u00e4mie im Rahmen eines Zellyse-Syndromes bei einem Kind mit T-ALL"],"prefix":"10.1159","author":[{"given":"H.","family":"Kabisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Niggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:05:03Z","timestamp":1777680303000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216604","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}